Drug intelligence / Profile preview

lactobacillus reuteri + bifidobacterium bifidum

Development stage: Preclinical
Lead developer: BioGaia
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus reuteri + Bifidobacterium bifidum is a combination of two probiotic bacterial strains. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. This specific combination is being investigated for its therapeutic effects, particularly in neonatal conditions like bronchopulmonary dysplasia (BPD). The proposed mechanism involves modulation of the gut-lung axis, where altering the gut microbiota can influence systemic inflammation and immune responses. A study on a BPD cell model showed that this combination promoted cell proliferation, inhibited apoptosis, and reduced inflammation and oxidative stress. Both Lactobacillus and Bifidobacterium species are known to have immunomodulatory properties, including enhancing the gut barrier, producing antimicrobial substances, and influencing cytokine production.

Targets

AJC (Intestinal epithelial junctional complex)

Beyond the preview

Go deeper on lactobacillus reuteri + bifidobacterium bifidum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus reuteri + bifidobacterium bifidum.

Explore the full profile